SEC Tracker
Get the app
ZBIO · XBRL financial data

Zenas BioPharma financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ZBIO's year ends in late December)

In millions of dollarsSep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue05*10000*—110
Revenue from contracts with customers—year only100*0*0*—110
Research and development3449*35433456*606358
General and administrative711*12121316*171627
Total operating expenses4161*475553238*77109113
Operating income (loss)(41)(56)*(37)(55)(53)(238)*(77)(108)(103)
Interest income—year only3333*376
Interest expense—————year only022
Other income (expense)23*431(7)*(0)0(0)
Income tax expense (benefit)—year only(0)00*0*—00
Net income (loss)(39)(53)*(34)(52)(51)(240)*(81)(111)(109)
Earnings per share, basic USD per share(5.02)—(0.80)(1.25)(1.22)—(1.46)(1.77)(1.65)
Earnings per share, diluted USD per share(5.02)—(0.80)(1.25)(1.22)—(1.46)(1.77)(1.65)
Weighted average shares, basic millions of shares8—42424253*566366
Weighted average shares, diluted millions of shares8—42424253*566366

Balance sheet

CSV

Fiscal quarters (ZBIO's year ends in late December)

In millions of dollarsSep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents36032019744116111500197178
Short-term investments2731116229175233217447408
Marketable securities2731118231186250218477469
Prepaid and other current assets755568131118
Total current assets394356318279297351730654603
Property and equipment, net000000000
Right-of-use asset011111112
Total assets403370334293322384748702675
Accounts payable151720867987
Accrued liabilities293928454554515754
Total current liabilities445749535263616664
Long-term debt————7379———
Lease liability, non-current—00000000
Total liabilities44584953126141412455463
Accumulated deficit(335)(387)(421)(473)(525)(765)(846)(958)(1,066)
Total stockholders' equity359312284240196242336247212
Total liabilities and equity403370334293322384748702675
Common shares outstanding (cover page) millions of shares424242425457636568

Cash flows

CSV

Fiscal quarters (ZBIO's year ends in late December)

In millions of dollarsSep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(39)(53)*(34)(52)(51)(240)*(81)(111)(109)
Stock-based compensation3*5*56*7*8*99*17*
Net cash from operating activities(31)*(39)*(37)(42)*(41)*(52)*(75)(57)*(58)*
Purchases of property and equipment0*0*00*0*0*00*0*
Net cash from investing activities(27)*(4)*(86)(112)*40*(93)*32(288)*(19)*
Net cash from financing activities234*2*02*73*141*43342*57*
Net change in cash176*(40)*(123)(153)*72*(5)*390(304)*(19)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Zenas BioPharma17810(58)*67.8M9.2 quarters 10-QSep 30, 2026
Atea Pharmaceuticals77not reported(37)*80.2M5.9 quarters 10-QJun 30, 2026
Verastem13640(44)*90.6M3.1 quarters 10-QJun 30, 2026
Corvus Pharmaceuticals19not reported(15)*84.1M14.0 quarters 10-QJun 30, 2026
DBV Technologies1661.6(52)*314.4M3.2 quarters 10-QSep 30, 2026
Vanda Pharmaceuticals6270(28)*60.5M1.7 quarters 10-QSep 30, 2026
Tonix Pharmaceuticals Holding17614(42)*17.2M4.2 quarters 10-QJun 30, 2026
Abeona Therapeutics5611(17)*57.2M8.4 quarters 10-QJun 30, 2026
Annexon199not reported(48)*not reported4.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.